Form 483

Mylan Laboratories Limited Form 483, 2019-05-24

FDA issued a Form 483 to Mylan Laboratories Limited on 2019-05-24 with 12 public-safe observations.

483· Form 483 issuedHuman Drugs12 observations

Mylan Laboratories Limited · Hosur, India · Issued May 24, 2019

Overview

  • 12 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

24 May 2019
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Anastasia M Shields, Jose E Melendez

24 May 2019
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Anastasia M Shields, Jose E Melendez

24 May 2019
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Anastasia M Shields, Jose E Melendez

24 May 2019
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Anastasia M Shields, Jose E Melendez

24 May 2019
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Anastasia M Shields, Jose E Melendez

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations4x
21 CFR 211.113(b)Cited across public-safe Form 483 observations2x
21 CFR 211.160(b)Cited across public-safe Form 483 observations2x
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations2x

Full 483 report

Get the verbatim text of all 12 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere